RTI Biologics (RTIX -13.5%) trades down into the close despite beating Q4 estimates. Profit actually declined 5.5% Y/Y due to inventory issues, which masked a 20% jump in international sales. The company warns on FY12 guidance however, now saying it expects revenue in the range of $174M - $176M. Analysts are looking for sales of $176M.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs